Federal Authorities Issue Warning on Drugs Used in MRI Scans

Some drugs used in MRI scans pose a fatal risk to patients with kidney problems, the U.S. Food and Drug Administration has warned.

The risk comes from the metal gadolinium, which is used in drugs injected into patients to produce clearer medical image scans of internal organs. The FDA warned that gadolinium-containing drugs can cause a potentially fatal condition known as nephrogenic systemic fibrosis in patients with kidney disease. An FDA review found that three drugs posed the highest risk of causing the condition — Magnevist, marketed by Bayer HealthCare, Omniscan by GE Healthcare, and Optimark by Covidien.

MRI imaging drugs containing gadolinium will now carry a warning label indicating that patients should be screened for kidney disease prior to using the drugs, and that physicians should avoid using the drugs in patients with severe kidney disease, or with impaired drug elimination.

GE Healthcare said in a statement that the labeling requirement reinforces existing guidelines urging physicians to screen MRI patients with kidney problems, according to The Associated Press. The company said MRI imaging drugs “continue to be a valuable diagnostic tool with a proven safety record for the overwhelming majority of patients to whom they are prescribed.”

Print Print  

Like what we're doing? We'd appreciate your support.

Leave a comment